124 related articles for article (PubMed ID: 37781828)
1. MiniMed 780GTM in children with type 1 diabetes under seven years of age: Prospective open-label, single-arm, double-center, follow-up study.
Seget S; Chobot A; Rusak E; Ochab A; Bielawska A; Polanska J; Jarosz-Chobot P
Technol Health Care; 2024; 32(3):1463-1472. PubMed ID: 37781828
[TBL] [Abstract][Full Text] [Related]
2. Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes.
Seget S; Rusak E; Polanska J; Jarosz-Chobot P
Diabetes Technol Ther; 2022 Nov; 24(11):824-831. PubMed ID: 35852811
[No Abstract] [Full Text] [Related]
3. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
[TBL] [Abstract][Full Text] [Related]
4. Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stable - 1-year prospective, observational, two-center study.
Seget S; Jarosz-Chobot P; Ochab A; Polanska J; Rusak E; Witoszek P; Chobot A
Front Endocrinol (Lausanne); 2022; 13():1036808. PubMed ID: 36303875
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.
Rapini N; Martino M; Arnaldi C; Deodati A; Anagnostopoulou L; Amodeo ME; Ciampalini P; Pampanini V; Lorubbio A; Tosini D; Cianfarani S; Schiaffini R
Front Endocrinol (Lausanne); 2024; 15():1382920. PubMed ID: 38836230
[TBL] [Abstract][Full Text] [Related]
6. Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.
Wheeler BJ; Collyns OJ; Meier RA; Betts ZL; Frampton C; Frewen CM; Galland B; Hewapathirana NM; Jones SD; Chan DSH; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; de Bock MI
Acta Diabetol; 2022 Jan; 59(1):31-37. PubMed ID: 34453208
[TBL] [Abstract][Full Text] [Related]
7. Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI).
Petrovski G; Al Khalaf F; Campbell J; Day E; Almajaly D; Hussain K; Pasha M; Umer F; Hamdan M; Khalifa A
BMC Endocr Disord; 2022 Mar; 22(1):80. PubMed ID: 35351095
[TBL] [Abstract][Full Text] [Related]
8. The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment.
Quirós C; Alonso-Carril N; Rodríguez-Rodríguez S; Barahona MJ; Orois A; Simó-Servat A; Ramos M; Perea V
Endocrinol Diabetes Nutr (Engl Ed); 2023 Feb; 70(2):130-135. PubMed ID: 36925230
[TBL] [Abstract][Full Text] [Related]
9. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
[No Abstract] [Full Text] [Related]
10. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
[TBL] [Abstract][Full Text] [Related]
11. The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes.
Jalilova A; Pilan BŞ; Demir G; Özbaran B; Balkı HG; Arslan E; Köse SG; Özen S; Darcan Ş; Gökşen D
Eur J Pediatr; 2024 Jul; 183(7):3095-3103. PubMed ID: 38661816
[TBL] [Abstract][Full Text] [Related]
12. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
13. Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies.
Schiaffini R; Lumaca A; Martino M; Rapini N; Deodati A; Amodeo ME; Ciampalini P; Matteoli MC; Pampanini V; Cianfarani S
Diabetes Metab Res Rev; 2024 Jul; 40(5):e3826. PubMed ID: 38824455
[TBL] [Abstract][Full Text] [Related]
14. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
[No Abstract] [Full Text] [Related]
15. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
16. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes with MiniMed
Abraham MB; Smith GJ; Dart J; Davis EA; Jones TW
Diabetes Technol Ther; 2024 May; 26(5):341-345. PubMed ID: 38215208
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two advanced hybrid closed loop in a pediatric population with type 1 diabetes: a real-life observational study.
Schiaffini R; Deodati A; Nicoletti MC; Carducci C; Ciampalini P; Lorubbio A; Matteoli MC; Pampanini V; Patera IP; Rapini N; Cianfarani S
Acta Diabetol; 2022 Jul; 59(7):959-964. PubMed ID: 35451679
[TBL] [Abstract][Full Text] [Related]
19. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
[TBL] [Abstract][Full Text] [Related]
20. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
